TSE:4568Pharmaceuticals
Daiichi Sankyo (TSE:4568) Stock Revenue Surges While Margins Stay Under Pressure
Daiichi Sankyo entered this earnings day with a stock that had drifted lower over the past week and three months, even as long term growth expectations and a discounted cash flow fair value estimate painted a more upbeat picture. The Q1 FY2027 print puts that gap in sharp focus. Total revenue reached ¥574.7b and basic earnings per share came in at ¥37.72, anchored by oncology drug sales. The key question for you now is whether a market that has marked the stock down is properly pricing the...